GABA Expansion in Japan and Overseas
First written in FY2016-Q3. 19 of 36 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-10-02.
2 other companies' latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「Revenue from functional ingredients was ¥1,308 million, up 38.3% year on year. The GABA market continued to expand, with sales of our flagship product, PharmaGABA, to supplement manufacturers in North America remaining strong. In Japan, PharmaGABA was adopted for daily foods sold through a major convenience-store chain.」
Revenue from functional ingredients was ¥1,308 million, up 38.3% year on year. In addition to strong sales to supplement manufacturers in North America, newly reported adoption in daily foods for a major convenience-store chain was noted. - FY2024AdvancedAnnual report
「Revenue from functional ingredients was ¥2,588 million, up 29.3% from the previous fiscal year. The GABA market continued to expand, with sales of our PharmaGABA flagship product to supplement manufacturers in North America remaining strong.」
Revenue from functional ingredients was ¥2,588 million, up 29.3% from the previous fiscal year, with strong sales of PharmaGABA to supplement manufacturers in North America reported. - FY2024-Q3AdvancedAnnual report
「Revenue from functional ingredients was ¥1,676 million, up 21.4% year on year. Sales of our flagship product, PharmaGABA, remained strong in Japan and overseas. In the domestic market in particular, 1,139 notifications had been filed for GABA under the Foods with Function Claims system as of 15 May 2024, compared with 891 in the same period of the previous year, and we continued to maintain the leading adoption record.」
Revenue from functional ingredients was ¥1,676 million, up 21.4% year on year, with strong domestic and overseas sales of PharmaGABA and an increase in GABA notifications reported. - FY2024-Q2AdvancedAnnual report
「Revenue from functional ingredients was ¥946 million, up 16.0% year on year. Sales of our flagship product, PharmaGABA, remained strong in Japan and overseas. In the domestic market in particular, 1,086 notifications had been filed for GABA under the Foods with Function Claims system as of the end of February 2024, compared with 824 in the same period of the previous year, and we continued to maintain the leading adoption record.」
Revenue from functional ingredients, including PharmaGABA, was ¥946 million, up 16.0% year on year. Strong domestic and overseas sales of GABA, along with 1,086 domestic notifications and the leading adoption record, were also reported. - FY2024-Q1RestatedAnnual report
「Revenue from functional ingredients was ¥504 million, up 34.3% year on year. Sales of our flagship product, PharmaGABA, remained strong in Japan and overseas,」
The company has continued to state that domestic and overseas sales of PharmaGABA have remained strong. - FY2023AdvancedAnnual report
「Revenue from functional ingredients was ¥2,002 million, up 17.2% from the previous fiscal year. Sales of our flagship product, PharmaGABA, remained strong.」
Revenue from functional ingredients, including PharmaGABA, was ¥2,002 million, up 17.2% from the previous fiscal year. - FY2023-Q2AdvancedAnnual report
「In sales of functional ingredients, revenue from PharmaGABA, our flagship product, was ¥564 million, up 23.6% year on year. In overseas markets, product adoption has been increasing in response to the post-COVID recovery in the United States.」
PharmaGABA revenue was ¥564 million, up 23.6% year on year, and increased product adoption in the United States was also reported. - FY2023-Q1AdvancedAnnual report
「In sales of functional ingredients, revenue from PharmaGABAⓇ, our flagship product, was ¥258 million, up 69.9% year on year. In overseas markets, adoption of the product has been increasing in response to the post-COVID recovery in the United States.」
PharmaGABA revenue increased 69.9% year on year, and increased product adoption in the United States was also reported. - FY2022WorsenedAnnual report
「In sales of functional ingredients, revenue from PharmaGABAⓇ, our flagship product, was ¥1,271 million, down 5.8% from the previous fiscal year. Overseas markets were affected, particularly by the lockdowns in China.」
Full-year GABA revenue was ¥1,271 million, down 5.8% from the previous fiscal year, indicating that the impact of China’s lockdowns was also reflected in full-year results. - FY2022-Q3WorsenedAnnual report
「In sales of functional ingredients, revenue from PharmaGABAⓇ, our flagship product, was ¥739 million, down 18.8% year on year. Overseas markets were affected, particularly by the lockdowns in China. In the domestic market, 685 notifications had been filed for GABA under the Foods with Function Claims system as of 17 May 2022, and we continued to maintain the leading adoption record. Food manufacturers continued to expand their adoption of GABA.」
PharmaGABA revenue declined 18.8% year on year, with the impact of China’s lockdowns explicitly cited. Meanwhile, the number of GABA notifications and expanded adoption by food manufacturers continued. - FY2022-Q2Declining sales alongside expanded adoptionAnnual report
「In sales of functional ingredients, revenue from PharmaGABAⓇ, our flagship product, was ¥456 million, down 20.9% year on year, reflecting a decline following the increase in overseas shipments in the fourth quarter of the previous fiscal year. In the domestic market, 625 notifications had been filed for GABA under the Foods with Function Claims system as of the end of January 2022, and we continued to maintain the leading adoption record. Food manufacturers continued to expand their adoption of GABA.」
While PharmaGABA revenue declined 20.9% year on year, the number of GABA notifications increased to 625, and the leading adoption record and expanded adoption by food manufacturers continued. - FY2022-Q1Declining sales alongside overseas expansion of applicationsAnnual report
「Revenue from PharmaGABAⓇ, our flagship product, was ¥152 million, down 27.1% year on year, reflecting a decline following the increase in overseas shipments in the fourth quarter of the previous fiscal year. In the domestic market, 568 notifications had been filed for GABA under the Foods with Function Claims system as of the end of October 2021, and we continued to maintain the leading adoption record. Food manufacturers continued to expand their adoption of GABA. In overseas markets, new products promoting sleep and muscle protein synthesis are scheduled for launch.」
PharmaGABA revenue declined 27.1% year on year, while GABA maintained the leading adoption record, and plans were announced to launch new products overseas promoting sleep and muscle protein synthesis. - FY2021AdvancedAnnual report
「Revenue from PharmaGABAⓇ, our flagship product, was ¥1,348 million, up 9.1% from the previous fiscal year.」
Full-year PharmaGABA revenue was ¥1,348 million, up 9.1% from the previous fiscal year. Adoption expanded overseas, including in North America, China and Southeast Asia, while strengthening overseas sales and establishing a stable supply system were also identified as issues to address. - FY2021-Q3Declining sales alongside expanded adoptionAnnual report
「Revenue from PharmaGABAⓇ, our flagship product, was ¥909 million, down 5.2% year on year. As of the end of April 2021, 479 notifications had been filed for GABA under the Foods with Function Claims system, and we continued to maintain the leading adoption record. The expansion of GABA adoption by food manufacturers has led to increased orders for our PharmaGABAⓇ, which holds the top market share.」
While PharmaGABA revenue declined 5.2% year on year, the number of GABA notifications and its adoption by food manufacturers increased, with sales performance and expanded adoption occurring in parallel. - FY2021-Q2AdvancedAnnual report
「In functional food ingredients, research and development is steadily contributing to business performance. For example, PharmaGABAⓇ is being shipped to a major beverage manufacturer as an ingredient that improves memory.」
Shipments of PharmaGABA for products aimed at major beverage manufacturers, promoting improved memory in addition to its conventional stress and sleep applications, have been reported, making its range of applications more concrete. - FY2021-Q1AdvancedAnnual report
「Several major beverage manufacturers are planning to sell foods with functional claims containing PharmaGABA® that promote the maintenance and improvement of cognitive function and stress relief, which is expected to contribute to sales from the cumulative second-quarter consolidated period onward. The new “sleep and muscle” concept has been accepted by various protein manufacturers, and its adoption in protein drinks and supplements is expected to contribute to sales from the second quarter onward.」
In Japan, major beverage manufacturers are planning to use GABA in products for cognitive function and stress relief, while overseas, plans call for its use in protein products based on the “sleep and muscle” concept, among others. GABA’s applications and sales channels are becoming more concrete. - FY2020-Q3AdvancedAnnual report
「In Japan, sales of PharmaGABA® increased 55.6% year on year to ¥612 million. Following its adoption by Japan’s largest beverage manufacturer in a flagship brand product, the GABA market continues to expand.」
Domestic sales of PharmaGABA increased 55.6% year on year to ¥612 million, and the disclosure describes GABA market expansion through its adoption by Japan’s largest beverage manufacturer. - FY2020-Q2AdvancedAnnual report
「In Japan, sales of PharmaGABA® increased 57.4% year on year to ¥415 million. The GABA market continues to expand, including the recent adoption of PharmaGABA® in a flagship brand product by Japan’s largest beverage manufacturer.」
Domestic sales of PharmaGABA increased 57.4% year on year to ¥415 million, and new adoption by Japan’s largest beverage manufacturer was also disclosed. - FY2020-Q1RestatedAnnual report
「Overseas, the company also expects sales to increase going forward, mainly in North America and China.」
The company continues its policy of expanding overseas and increasing sales in North America and China, centered on GABA. - FY2019RaisedAnnual report
「In sales, the company will strengthen its personnel serving overseas markets and focus not only on its core markets of North America and China but also on expansion in Southeast Asia, where the market is expected to grow.」
In addition to its previous overseas expansion focused on North America and China, Southeast Asia has been identified as an additional priority region. - FY2019-Q3RestatedAnnual report
「GABA, which supports functional claims for “stress relief,” “reduced fatigue,” “improved sleep quality” and “blood pressure,” continues to receive inquiries from many food and beverage manufacturers, and further growth is expected. It is also performing steadily overseas.」
The company has reconfirmed that GABA’s business with domestic manufacturers and its international business are both performing steadily. - FY2019-Q2RestatedAnnual report
「The international business also performed well in both North America and China.」
The company has reconfirmed that the international business, including GABA, is performing well in North America and China. - FY2019-Q1RestatedAnnual report
「The international business also performed very strongly during the period. GABA continued to progress steadily in both North America and China.」
The company continues to expand GABA internationally, focusing mainly on North America and China. No specific additional milestones, such as new regions or adoption volumes, are described. - FY2018-Q3RestatedAnnual report
「In the international business, the company continues to focus on GABA in both North America and China, while Bonepep has also performed steadily in China, contributing to the expansion of the functional ingredients business.」
The company continues to expand GABA internationally, focusing mainly on North America and China, while Bonepep has also performed steadily in China. - FY2018-Q2RestatedAnnual report
「In the international business, the company continues to focus on GABA in both North America and China, while Bonepep has also performed steadily in China, contributing to the expansion of the functional ingredients business.」
The company continues to expand GABA internationally, focusing mainly on North America and China. - FY2018-Q1RestatedAnnual report
「In the international expansion of GABA, sales activities are focused mainly on China, North America and other markets. In China, our GABA has been adopted by several global manufacturers. In North America, our GABA has been adopted in “stress” and “sleep” supplements, and performance has been strong.」
The disclosure continues to describe GABA’s international sales activities focused on China and North America, as well as its adoption record in both regions. - FY2017-Q3RestatedAnnual report
「In the international expansion of GABA, sales activities are focused mainly on China, North America and other markets. In China, our GABA has been adopted by several global manufacturers since the previous fiscal year. In North America, our GABA has been adopted in supplement products, and performance has been steady.」
The disclosure continues to describe GABA’s international sales activities focused on China and North America, as well as its adoption record in both regions. - FY2017-Q2AdvancedAnnual report
「In North America, our GABA has been adopted in supplement products, and performance has remained firm.」
Regarding GABA’s international expansion, the disclosure now specifically describes its adoption in supplement products in North America and firm performance, in addition to the previous focus on China. - FY2017-Q1RestatedAnnual report
「During the cumulative first-quarter consolidated period, we continued to focus on the development of GABA.」
The company continues its policy of developing GABA domestically and internationally as a key product. - FY2016-Q3First statedAnnual report
「During the cumulative third-quarter consolidated period, we continued to focus on the development of GABA.」
GABA is being developed as a key product in the functional ingredients business.